Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Summary
-Results to be presented at ARVO 2026 Annual Meeting-
Description
-Results to be presented at ARVO 2026 Annual Meeting-
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source